Answers are grounded in this paper and cite their sources.
To the Editor: X-linked lymphoproliferative disease type 1 (XLP-1, SLAM-associated protein [SAP] deficiency) is caused by hemizygous loss-of-function mutations in the gene SH2D1A [1-4], which encodes SAP. The protein, mainly expressed in T, NK, and NKT cells, binds via its Src homology 2 (SH2) domain to signaling lymphocytic activation molecule (SLAM) and SLAM-related receptors on the surface of hematopoietic cells [5], acting as a molecular switch between activating or inhibitory functions of these receptors. A hallmark of XLP-1 is the impaired T/B-cell interaction leading to hypogammaglobulinemia, B-cell lymphoma, and impaired T-cell mediated control of Epstein–Barr virus (EBV) infected B cells with massive T-cell activation, frequently resulting in hemophagocytic lymphohistiocytosis (HLH) and peripheral cytopenia [6, 7]. NK-cell cytotoxicity and NK/B-cell interactions are also impaired [8], and along with NKT deficiency, contribute to EBV infection control failure. Aplastic anemia (AA) is a T-cell mediated disorder characterized by pancytopenia and hypoplastic bone marrow (BM). Here, we report two unrelated children with previously undiagnosed SAP deficiency, who initially presented with AA without prior EBV infection. Immunological symptoms usually not related to AA led to diagnosis of the genetic condition. Case 1: A 4-year-old boy developed severe pancytopenia (Table S1) following gastroenteritis. His medical history included enteropathy with proctitis and failure to thrive since the age of 3 years. BM features were consistent with AA (Figure 1A,B, Table S1). Gastro/colonoscopy suggested autoimmune enteropathy (Figure 1C), prompting further immunological investigation. IgG, IgA, and IgE levels were normal, whereas IgM was slightly elevated (Table 1). Flow cytometry showed a lack of NKT cells, decreased CD56 + CD16 + NK cells and class-switched and transitional B cells, and absent SAP expression in T and NK cells. Sanger sequencing identified a novel nonsense SH2D1A variant (c.141T > G; p.Tyr47*), confirming SAP deficiency. EBV-polymerase chain reaction (PCR) and serostatus in peripheral blood were negative. Enteropathy was treated with steroid. He underwent a human leucocyte antigen (HLA)-matched unrelated donor hematopoietic stem cell transplantation (HSCT) and remains well. Case 2: A 2-year-old boy was diagnosed with pancytopenia (Table S1) after admission for fever of unknown origin and generalized confluent macular exanthema. The BM biopsy was compatible with AA (Figure 1D, Table S1). The patient then developed upper gastrointestinal bleeding, aspergillus pneumonia, and nasopharyngeal aspergilloma 1 month later, which finally triggered the secondary HLH. The patient received granulocyte infusions. The unusual inflammatory manifestation led to consideration of an underlying immunodeficiency. Immunoglobulin levels were normal. Flow cytometry showed numerically normal T- and B-cell compartments, but lack of SAP expression in T and NK cells (Figure 1F). A whole genome sequencing revealed a known nonsense variant in SH2D1A (c.163C > T; p.Arg55*). Peripheral blood EBV-PCR and the EBV serostatus were negative. The patient was treated according to the HLH 2004 protocol [9]. The patient died of aspergillosis complicated by gastric perforation with massive bleeding during the pre-HSCT conditioning. Gastric histology confirmed disseminated aspergillosis and extensive transmural necrosis (Figure 1E). We report two unrelated patients diagnosed with XLP-1 upon presentation with AA without prior EBV infection. Both had unusual clinical manifestations with history of colitis (Patient 1) and generalized exanthema and subsequent aspergillus-associated HLH (Patient 2), suggesting an underlying immunological disease. A recent cohort study reported AA in 4% of SAP-deficient patients (3/79) [10]. We identified 12 additional XLP-1 cases with AA in the literature [11-20], with detailed descriptions for 8 (Table 1). The median age of 10 patients, including our 2 cases at first manifestation of XLP-1 and AA, was 4 and 5 years, respectively. Importantly, AA can be the first manifestation of the XLP-1 (4/10 patients), suggesting that XLP-1 should be considered a possible differential diagnosis in patients presenting with AA [16, 18, 20]. Careful evaluation of the patient's history for other immune-related manifestations and examination of SAP expression can lead to early diagnosis of XLP-1. Additional immunological findings included hypogammaglobinemia, absent or reduced antibody responses to vaccines [13, 14], absent NK or NKT cells [19], and decreased class-switched B cells [14]. Importantly, EBV-PCR was negative in six of nine patients examined [17, 19], showing that AA in XLP-1 is not always triggered by EBV infection. Three patients developed lymphoma, and three were diagnosed with HLH. All four patients who underwent HSCT are alive, whereas the others died from infection [13, 15], underscoring the need for early XLP-1 diagnosis and treatment with HSCT. The histological findings of BM in patients with XLP-1 and AA have been poorly described. The BM in our two patients was completely aplastic and, at first sight, indistinguishable from idiopathic AA. However, prominent interstitial edema and prominent T-cell infiltration were observed in both patients as well as in another case reported by Halasa et al. [15]. These findings are not specific but are compatible with uncontrolled T-cell activation in XLP-1. Histological differentiation between secondary HLH and AA in XLP-1 may be difficult in some cases, as BM cellularity in HLH can vary (sometimes hypoplastic) [21], and signs of hemophagocytosis in BM may be subtle. The pathogenesis of AA in XLP-1 is not fully understood. AA is a T-cell mediated disease characterized by BM hypoplasia and severely reduced hematopoietic stem cells [22], with characteristic autoreactive T-cell clones and a Th1-skewed cytokine profile in BM [23, 24]. The pathogenic role of interferon-gamma (IFN-γ) has been well described in AA [25]. In XLP-1, the downstream signaling of SLAM receptors is altered, which may, in turn, promote Th1 polarization and INF-γ secretion [26]; thus, it can be speculated that some SAP-deficient patients are prone to develop BM failure. Further studies are needed to clarify whether this process is T-cell mediated and antigen-specific or not and how this ultimately leads to AA. Additionally, in the context of SAP deficiency, EBV or other infections may lead to immune dysregulation and enhanced Th1 polarization and may thereby trigger HLH with uncontrolled T/NK-cell activation and IFN-γ secretion, ultimately resulting in BM suppression. In summary, patients with XLP-1 can initially present with AA, and patients with atypical symptoms like colitis, generalized exanthema, or systemic inflammation should undergo an immunological work-up for XLP-1, even in the absence of a positive family history or EBV infection. We thank Anne Breier and Elena Huber for their assistance with data management. The authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Toskov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: